Protein kinases play an important role in the catalytic activity and signaling functional transduction of critical cellular processes. TTK, also called monopolar spindle 1 (Mps1), is a dual specificity kinase that causes the phosphorylation of both tyrosine and serine/threonine residues. It is one of the spindle assembly checkpoint (SAC) that facilitates the alignment of chromosomes on the metaphase plate in mitosis which is associated with the progression of the cell cycle. TTK is essential for the right alignment of all chromosomes, and subsequently, correct attachment to the mitotic spindle. Targeting this kinase may effectively block chromosome segregation during mitosis, and it could be a great invention for cancer therapy.
Market Dynamics
The increased per capita healthcare spending has enhanced research and development activities for the treatment of chronic diseases, which is expected to drive the global dual specificity protein kinase TTK inhibitors market growth over the forecast period. According to the World Bank estimates in 2019, the per capita healthcare expenditure increased significantly in Latin America. The healthcare expenditure in Latin America was around US$ 638 Mn in 2016, which increased to US$ 666 Mn by 2018.
Increasing approvals for product launches by the regulatory bodies is also expected to drive the market growth over the forecast period. For instance, in January 2019, Dacomitinib, a selective and irreversible inhibitor of EGFR by Pfizer Inc., a leading research-based biopharmaceutical company, received approval from the Ministry of Health, Labour and Welfare of Japan for the treatment of EGFR mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC).
Key features of the study:
- This report provides in-depth analysis of the global dual specificity protein kinase TTK inhibitors market, market size (US$ Mn), and the compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dual specificity protein kinase TTK inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, Pfizer Inc., Boston Pharmaceuticals, Nerviano Medical Sciences S.R.L (Part of NMS group), and Servier Laboratories
- Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dual specificity protein kinase TTK inhibitors market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dual specificity protein kinase TTK inhibitors market
Detailed Segmentation:
- Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Product Type:
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Application:
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Region:
- North America
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Country
- Latin America
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Product Type
- BAY 1217389
- BOS-172722
- CFI-402257
- S 81694
- Others
- Application
- Non-hematologic Malignancies
- Breast Cancer
- Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Bayer AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Boston Pharmaceuticals
- Nerviano Medical Sciences S.R.L (Part of NMS group)
- Servier Laboratories.
“*” marked represents similar segmentation in other categories in the respective section.
